Boston Scientific has completed the acquisition of BTG. BTG develops and commercialises products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. 

BTG has three key businesses, an interventional medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease.

Mike Mahoney, chairman and chief executive officer of Boston Scientific said: “The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world. Leveraging the employee talent and clinical and commercial expertise of these two high-performing organisations will generate continued innovation and access so that we may advance patient care in ways that neither company could do alone.” 

In addition to the Interventional Medicine product lines, the BTG portfolio also includes a specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties related to BTG intellectual property and product license agreements.

Upon the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific, and BTG shares no longer trade on the London Stock Exchange. Under the terms of the previously announced transaction, holders of BTG common shares will receive 840 pence in cash per share. 

Boston Scientific expects to complete the previously announced sale of its global embolic microspheres portfolio – comprised of Embozene, Embozene Tandem and Oncozene brands – to Varian Medical Systems, in due course, a transaction entered into in connection with obtaining the antitrust clearances required to complete the BTG transaction.   

In addition, the company is initiating a process to explore the divestiture of the royalty stream associated with BTG’s Zytiga licensing arrangements and anticipates closing this divestiture by the end of 2019.

LEAVE A REPLY

Please enter your comment!
Please enter your name here